Autism Spectrum Disorder (ASD) Research
Trend
Precision medicine approaches for ASD underscore the need for targeted therapies to address the heterogeneity of the disorder.
Trendsetters
Stalicla’s specific focus on precision ASD assets, such as the STP1 Phase 2 trial and the STP2 asset, highlights a trend in the industry towards advancing research and development efforts in the field of autism. Funding $25.4 million.